Rigel Initiates Phase 2 Clinical Studies with R343 for Asthma and R333 for ... The Herald | HeraldOnline.com ... R343, an inhaled SYK inhibitor for asthma and R333, a topical JAK/SYK inhibitor for discoid lupus – both of which have commenced Phase 2 clinical trials; and R548, an oral JAK3 inhibitor for the treatment of transplant rejection and other immune ... |
